Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

New findings from the EVEREST Phase 4 trial presented at the 2025 EAACI Congress reveal that Dupixent (dupilumab ... 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed ...

“Our higher target reflects confidence in Dupilumab’s commercial COPD opportunity, adding to our already positive outlook for Regeneron on an ophthalmology franchise renewed by 8mg ...

Data from prior Sanofi/Regeneron studies further supports ... on high-dose ICS plus placebo. The VESTIGE trial, meanwhile, demonstrated that dupilumab led to reductions in mucus plugging and ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Study C is an ongoing trial investigating Dupixent in the same population as Study A. About Dupixent Dupixent, which was invented using ... with Dupixent globally. Dupilumab Development Program ...

Dupilumab is a human monoclonal antibody ... was developed by the trial sponsors (Sanofi and Regeneron Pharmaceuticals) and three of the authors. Data were collected by the investigators and ...

The safety profile of dupilumab was consistent with that observed in previous clinical trials. Adverse events ... President and Chief Scientific Officer at Regeneron, and a principal inventor ...